ArticleExperimental hematology & oncology2025

Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults.

Víctor Galán-Gómez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.